Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 24:(128):55835.
doi: 10.3791/55835.

Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain

Affiliations

Enrichment of Detergent-insoluble Protein Aggregates from Human Postmortem Brain

Ian Diner et al. J Vis Exp. .

Abstract

In this study, we describe an abbreviated single-step fractionation protocol for the enrichment of detergent-insoluble protein aggregates from human postmortem brain. The ionic detergent N-lauryl-sarcosine (sarkosyl) effectively solubilizes natively folded proteins in brain tissue allowing the enrichment of detergent-insoluble protein aggregates from a wide range of neurodegenerative proteinopathies, such as Alzheimer's disease (AD), Parkinson's disease and amyotrophic lateral sclerosis, and prion diseases. Human control and AD postmortem brain tissues were homogenized and sedimented by ultracentrifugation in the presence of sarkosyl to enrich detergent-insoluble protein aggregates including pathologic phosphorylated tau, the core component of neurofibrillary tangles in AD. Western blotting demonstrated the differential solubility of aggregated phosphorylated-tau and the detergent-soluble protein, Early Endosome Antigen 1 (EEA1) in control and AD brain. Proteomic analysis also revealed enrichment of β-amyloid (Aβ), tau, snRNP70 (U1-70K), and apolipoprotein E (APOE) in the sarkosyl-insoluble fractions of AD brain compared to those of control, consistent with previous tissue fractionation strategies. Thus, this simple enrichment protocol is ideal for a wide range of experimental applications ranging from Western blotting and functional protein co-aggregation assays to mass spectrometry-based proteomics.

PubMed Disclaimer

References

    1. Taylor JP, Hardy J, Fischbeck KH. Toxic Proteins in Neurodegenerative Disease. Science. 1991;296(5575):1991. - PubMed
    1. Ross CA, Poirier MA. Protein aggregation and neurodegenerative disease. Nature Medicine. 2004;10:S10–S17. - PubMed
    1. Ramírez-Alvarado M, Merkel JS, Regan L. A systematic exploration of the influence of the protein stability on amyloid fibril formation in vitro. Proc. Natl. Acad. Sci. 2000;97(16):8979–8984. - PMC - PubMed
    1. Hamley IW. The Amyloid Beta Peptide: A Chemist's Perspective. Role in Alzheimer's and Fibrillization. Chem Rev. 2012;112(10):5147–5192. - PubMed
    1. Diner I, et al. Aggregation Properties of the Small Nuclear Ribonucleoprotein U1-70K in Alzheimer Disease. J. Biol. Chem. 2014;289(51):35296–35313. - PMC - PubMed

Publication types